Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Vildagliptin Versus NPH Insulin add-on to Glimepiride in Type 2 Diabetes Mellitus Patients.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of type 2 diabetes mellitus.~* Contraindicated or intolerant to take metformin.~* HbA1c of ≥ 7.0% and ≤ 8.5%~* Current sulfonylurea (glimepiride) monotherapy and judged by the investigator to be inadequately controlled~* Other protocol-defined inclusion/exclusion criteria may apply~Exclusion Criteria:~* Patients who are taking any other anti-diabetes drug (oral or injection) other than an SU component in the preceding 12 weeks.~* Acute metabolic conditions such a ketoacidosis, lactic acidosis or hyperosmolar state within the past 6 month~* Patients taking sulfonylurea for longer than 5 years~* History of hypersensitivity to any of the study drugs or to drugs with similar chemical structures~* pregnancy~* Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Vildagliptin (Type: EXPERIMENTAL): Patients randomized to the vildagliptin group will receive 50mg vildagliptin once daily add-on to their current glimepiride monotherapy for 24 weeks. No dose titrations are permitted during the study.
- Protaphane (Type: ACTIVE_COMPARATOR): Patients randomized to the Protaphane group will receive a individualized dose of Protaphane once daily as bedtime dose. The Protaphane dose will be titrated within the first 4 weeks to reach fasting plasma glucose values below 100 mg/dl.

Based on this trial design, predict the completion outcome and termination type (if applicable).